Jallal Bahija - 25 Jan 2024 Form 3 Insider Report for ArriVent Biopharma, Inc. (AVBP)

Role
Director
Signature
/s/ James Kastenmayer, Attorney-in-Fact for Bahija Jallal
Issuer symbol
AVBP
Transactions as of
25 Jan 2024
Net transactions value
$0
Form type
3
Filing time
25 Jan 2024, 20:36:17 UTC
Previous filing
02 Jan 2024
Next filing
21 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AVBP Stock Option (right to buy) 25 Jan 2024 Common Stock 13,149 $2.28 Direct F1, F2
holding AVBP Stock Option (right to buy) 25 Jan 2024 Common Stock 6,574 $3.65 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option vest over a three-year period with one third vesting on each anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date.
F2 Reflects the 15.21-for-1 reverse stock split of the Issuer's common stock effected on January 23, 2024 in connection with the Issuer's initial public offering, pursuant to which (i) the number of shares of common stock underlying the option was divided by 15.21 and (ii) the exercise price of the option was multiplied by 15.21.
F3 The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney